Newsfeeds - Spark Newswire

1 minute read

SVB Leerink Initiates Coverage On Horizon Therapeutics with Market Perform Rating, Announces Price Target of $95

Today, 6:14 AM

SVB Leerink analyst David Risinger initiates coverage on Horizon Therapeutics (NASDAQ:HZNP) with a Market Perform rating and announces Price Target of $95.

HZNP

4 minute read

FDA
News

Horizon Therapeutics Announces First Patient Enrolled In Phase 2 Trial Evaluating Daxdilimab (HZN-7734) For The Treatment Of Alopecia Areata

By Benzinga Newsdesk

Today, 6:14 AM

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab (HZN-7734) for the Treatment of Alopecia Areata Horizon Therapeutics plc (NASDAQ:HZNP) today announced the first patient

HZNP

27 minute read

Earnings Scheduled For May 4, 2022

By Benzinga Insights

Today, 6:14 AM

Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.

ABC

4 minute read

Options

10 Health Care Stocks With Whale Alerts In Today’s Session

By Benzinga Insights

Today, 6:14 AM

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

ABBV

1 minute read

Horizon Therapeutics’ Inebilizumab Scores European Approval For Spinal Cord Inflammation

By Vandana Singh

Today, 6:14 AM

The European Commission has approved Horizon Therapeutics plc’s (NASDAQ:HZNP) Uplizna (inebilizumab) as monotherapy for neuromyelitis optica spectrum disorder (NMOSD) who are…

HZNP

2 minute read

Executives Sell More Than $262M Of 5 Stocks

By Lisa Levin

Today, 6:14 AM

Although gold futures traded higher on Monday, there were a few notable insider trades.

GTES

3 minute read

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight

By Shanthi Rexaline

Today, 6:14 AM

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the holiday-shortened week before making a comeback.

ACAD

2 minute read

Horizon Therapeutics Announces New Analysis Demonstrates UPLIZNA Reduces Severity Of Attacks Associated With Neuromyelitis Optica Spectrum Disorder

By Benzinga Newsdesk

Today, 6:14 AM

Horizon Therapeutics plc (NASDAQ:HZNP) today announced results from a new analysis showing treatment with UPLIZNA effectively reduced the severity of attacks in people with NMOSD. These data are being presented at the

HZNP

2 minute read

FDA
News

Horizon Therapeutics Highlights Post-Marketing Safety Analysis Of TEPEZZA

By Benzinga Newsdesk

Today, 6:14 AM

Horizon Therapeutics plc (NASDAQ:HZNP) today announced results from a new post-marketing safety analysis of hearing events associated with TEPEZZA for the treatment of Thyroid Eye Disease (TED). These findings, along

HZNP

7 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For December 8, 2021

By Benzinga Insights

Today, 6:14 AM

ALLE